MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 146 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $56,634,624 | +109.4% | 202,151 | +99.6% | 0.01% | +150.0% |
| Q1 2024 | $27,048,229 | +23.6% | 101,289 | +7.1% | 0.00% | 0.0% |
| Q4 2023 | $21,889,242 | +36.0% | 94,603 | -14.2% | 0.00% | +33.3% |
| Q3 2023 | $16,095,360 | -13.2% | 110,212 | +37.2% | 0.00% | 0.0% |
| Q2 2023 | $18,551,379 | -46.4% | 80,309 | -43.8% | 0.00% | -62.5% |
| Q1 2023 | $34,640,999 | -27.1% | 142,991 | -12.7% | 0.01% | -33.3% |
| Q4 2022 | $47,540,338 | +405361.3% | 163,791 | -9.2% | 0.01% | +300.0% |
| Q3 2022 | $11,725 | +211.3% | 180,402 | +242.8% | 0.00% | +200.0% |
| Q2 2022 | $3,767 | -99.9% | 52,626 | +8.3% | 0.00% | 0.0% |
| Q1 2022 | $4,767,000 | -46.7% | 48,588 | -53.9% | 0.00% | -50.0% |
| Q4 2021 | $8,938,000 | -27.8% | 105,479 | -32.0% | 0.00% | -33.3% |
| Q3 2021 | $12,381,000 | +16.3% | 155,170 | +42.0% | 0.00% | +50.0% |
| Q2 2021 | $10,646,000 | +2.4% | 109,287 | +23.0% | 0.00% | -33.3% |
| Q1 2021 | $10,392,000 | +15.8% | 88,846 | +10.1% | 0.00% | +50.0% |
| Q4 2020 | $8,973,000 | -45.0% | 80,708 | -41.3% | 0.00% | -60.0% |
| Q3 2020 | $16,326,000 | +37.8% | 137,502 | +31.5% | 0.01% | +25.0% |
| Q2 2020 | $11,846,000 | -12.1% | 104,597 | -48.2% | 0.00% | -20.0% |
| Q1 2020 | $13,477,000 | -10.2% | 201,867 | +22.5% | 0.01% | +25.0% |
| Q4 2019 | $15,015,000 | +67.1% | 164,801 | +58.1% | 0.00% | +33.3% |
| Q3 2019 | $8,987,000 | -18.5% | 104,234 | -0.9% | 0.00% | 0.0% |
| Q2 2019 | $11,023,000 | -27.9% | 105,171 | -13.9% | 0.00% | -40.0% |
| Q1 2019 | $15,292,000 | +54.7% | 122,088 | +39.2% | 0.01% | +66.7% |
| Q4 2018 | $9,886,000 | -34.8% | 87,710 | +23.8% | 0.00% | -25.0% |
| Q3 2018 | $15,174,000 | +38.3% | 70,865 | +80.6% | 0.00% | +33.3% |
| Q2 2018 | $10,975,000 | +3373.1% | 39,242 | +1350.2% | 0.00% | – |
| Q1 2018 | $316,000 | -31.0% | 2,706 | -45.8% | 0.00% | – |
| Q4 2017 | $458,000 | +42.7% | 4,993 | -76.0% | 0.00% | – |
| Q1 2017 | $321,000 | +109.8% | 20,836 | +73.0% | 0.00% | – |
| Q3 2016 | $153,000 | – | 12,043 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 73,487 | $17,003,422 | 28.29% |
| Tao Capital Management LP | 130,529 | $30,202 | 27.63% |
| Paulson & Co. | 1,105,741 | $255,846,353 | 23.09% |
| AlpInvest Partners B.V. | 211,488 | $48,934,093 | 11.18% |
| Bain Capital Life Sciences Investors, LLC | 324,619 | $75,110,344 | 7.20% |
| Avoro Capital Advisors LLC | 1,888,888 | $437,050,905 | 6.04% |
| Propel Bio Management, LLC | 30,032 | $6,948,804 | 5.76% |
| Baker Brothers Advisors | 1,969,798 | $455,771,861 | 5.19% |
| Rosalind Advisors, Inc. | 25,000 | $5,784,500 | 4.76% |
| TCG Crossover Management, LLC | 179,917 | $41,629,195 | 4.62% |